183 related articles for article (PubMed ID: 34673795)
1. Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
Cremer S; Pilgram L; Berkowitsch A; Stecher M; Rieg S; Shumliakivska M; Bojkova D; Wagner JUG; Aslan GS; Spinner C; Luxán G; Hanses F; Dolff S; Piepel C; Ruppert C; Guenther A; Rüthrich MM; Vehreschild JJ; Wille K; Haselberger M; Heuzeroth H; Hansen A; Eschenhagen T; Cinatl J; Ciesek S; Dimmeler S; Borgmann S; Zeiher A;
PLoS One; 2021; 16(10):e0258684. PubMed ID: 34673795
[TBL] [Abstract][Full Text] [Related]
2. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
3. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
4. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
5. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
[TBL] [Abstract][Full Text] [Related]
6. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
Melissa Hallow K; Dave I
Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
[TBL] [Abstract][Full Text] [Related]
7. In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients.
Li S; Sarangarajan R; Jun T; Kao YH; Wang Z; Hao K; Schadt E; Kiebish MA; Granger E; Narain NR; Chen R; Schadt EE; Li L
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34411004
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
Lebek S; Tafelmeier M; Messmann R; Provaznik Z; Schmid C; Maier LS; Birner C; Arzt M; Wagner S
Eur J Heart Fail; 2020 Dec; 22(12):2248-2257. PubMed ID: 33017071
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
[TBL] [Abstract][Full Text] [Related]
10. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
[TBL] [Abstract][Full Text] [Related]
11. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
Rizk JG; Wenziger C; Tran D; Hashemi L; Moradi H; Streja E; Ahluwalia A
Drugs; 2022 Jan; 82(1):43-54. PubMed ID: 34914085
[TBL] [Abstract][Full Text] [Related]
13. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
[TBL] [Abstract][Full Text] [Related]
14. Influence of renin-angiotensin-aldosterone system inhibitors on plasma levels of angiotensin-converting enzyme 2.
Zimmermann T; Walter JE; Lopez-Ayala P; Strebel I; Amrein M; Koechlin M; Honegger U; Mueller C;
ESC Heart Fail; 2021 Apr; 8(2):1717-1721. PubMed ID: 34596976
[TBL] [Abstract][Full Text] [Related]
15. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
17. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
18. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
Hakeam HA; Alsemari M; Duhailib ZA; Ghonem L; Alharbi SA; Almutairy E; Sheraim NMB; Alsalhi M; Alhijji A; AlQahtani S; Khalid M; Barry M
J Cardiovasc Pharmacol Ther; 2021 May; 26(3):244-252. PubMed ID: 33231487
[TBL] [Abstract][Full Text] [Related]
19. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
20. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension.
Kuzeytemiz M; Tenekecioglu E
J Investig Med; 2022 Mar; 70(3):786-791. PubMed ID: 34987107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
